Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Blight

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 19, 2007
Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging studyA D Goodman, J A Cohen, A Cross, et al.
Topics in Spinal Cord Injury Rehabilitation|August 14, 2024
Data Safety Monitoring Boards: Overview of Structure and Role in Spinal Cord Injury StudiesAndrew R Blight, James D Guest, James Hamer, et al.
Restorative Neurology and Neuroscience|May 10, 2011
Effects of applied electric fields on clinical cases of complete paraplegia in dogsR B Borgens, J P Toombs, A R Blight, et al.
Spinal Cord|June 15, 2006
Phase 2 trial of sustained-release fampridine in chronic spinal cord injuryD D Cardenas, J Ditunno, V Graziani, et al.
Clinical Therapeutics|November 14, 2015
Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled TrialAngela Applebee, Andrew D Goodman, Angeli S Mayadev, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 14, 2015
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trialsAndrew D Goodman, Francois Bethoux, Theodore R Brown, et al.
Journal of Clinical Pharmacology|May 2, 2003
Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injuryK C Hayes, M A Katz, J G Devane, et al.
Lancet (London, England)|March 3, 2009
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialAndrew D Goodman, Theodore R Brown, Lauren B Krupp, et al.
Annals of Neurology|October 27, 2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosisAndrew D Goodman, Theodore R Brown, Keith R Edwards, et al.
Paraplegia|April 1, 1993
Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injuryK C Hayes, A R Blight, P J Potter, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 19, 2007
Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging studyA D Goodman, J A Cohen, A Cross, et al.
Topics in Spinal Cord Injury Rehabilitation|August 14, 2024
Data Safety Monitoring Boards: Overview of Structure and Role in Spinal Cord Injury StudiesAndrew R Blight, James D Guest, James Hamer, et al.
Restorative Neurology and Neuroscience|May 10, 2011
Effects of applied electric fields on clinical cases of complete paraplegia in dogsR B Borgens, J P Toombs, A R Blight, et al.
Spinal Cord|June 15, 2006
Phase 2 trial of sustained-release fampridine in chronic spinal cord injuryD D Cardenas, J Ditunno, V Graziani, et al.
Clinical Therapeutics|November 14, 2015
Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled TrialAngela Applebee, Andrew D Goodman, Angeli S Mayadev, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 14, 2015
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trialsAndrew D Goodman, Francois Bethoux, Theodore R Brown, et al.
Journal of Clinical Pharmacology|May 2, 2003
Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injuryK C Hayes, M A Katz, J G Devane, et al.
Lancet (London, England)|March 3, 2009
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialAndrew D Goodman, Theodore R Brown, Lauren B Krupp, et al.
Annals of Neurology|October 27, 2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosisAndrew D Goodman, Theodore R Brown, Keith R Edwards, et al.
Paraplegia|April 1, 1993
Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injuryK C Hayes, A R Blight, P J Potter, et al.
Pageof 12